Back to Search
Start Over
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
- Source :
- Nature; 3/18/2010, Vol. 464 Issue 7287, p405-408, 4p, 1 Diagram, 3 Charts, 2 Graphs
- Publication Year :
- 2010
-
Abstract
- Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00280836
- Volume :
- 464
- Issue :
- 7287
- Database :
- Complementary Index
- Journal :
- Nature
- Publication Type :
- Academic Journal
- Accession number :
- 48642603
- Full Text :
- https://doi.org/10.1038/nature08825